Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 82

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 82
---
 Stock. Enfusion Stockholders may call toll-free at (877) 750-0637, and banks and brokers may call collect at (212) 750-5833.

49

PROPOSAL 1: THE MERGER AGREEMENT PROPOSAL

As discussed throughout this Proxy Statement/Prospectus, Enfusion is asking its stockholders to approve the Merger Agreement Proposal.
Pursuant to the Merger Agreement, (i) Merger Sub II will merge with and into Enfusion OpCo, with Enfusion OpCo surviving the LLC Merger and becoming an indirect subsidiary of Clearwater, (ii) Merger Sub will merge with and into Enfusion,
with Enfusion surviving the Merger and becoming a direct, wholly-owned subsidiary of Clearwater, and (iii) following the Effective Time and subject to the satisfaction or waiver of the conditions specified in the Merger Agreement on the Closing
Date but prior to the Effective Time, Enfusion, the surviving company of the Merger, will merge with and into Acquirer, with Acquirer surviving the Second Merger as a direct, wholly-owned subsidiary of Clearwater. The Merger Agreement Proposal that
Enfusion is asking its stockholders to approve is the adoption of the Merger Agreement and approval of the Mergers. If the Transactions are completed, Enfusion will cease to be publicly traded and Enfusion Common Stock will be delisted from the NYSE
and deregistered under the Exchange Act.

As described in further detail in the sections titled “Questions and Answers,”
“Summary,” “The Transactions” and “The Merger Agreement,” the Enfusion Board has unanimously approved the Merger Agreement and the Transactions. For a discussion of certain factors considered by the Enfusion Board in
determining to approve the Merger Agreement and recommend that Enfusion Stockholders vote for the Merger Agreement Proposal, see the section titled “The Transactions—Enfusion’s Reasons for the Transactions; Recommendations of the
Special Committee and the Enfusion Board.” A copy of the Merger Agreement is attached as Annex A to this Proxy Statement/Prospectus. You are urged to read the Merger Agreement carefully and in its entirety.

The Transactions are subject to the satisfaction of the conditions set forth in the Merger Agreement, including approval of the Merger
Agreement Proposal by Enfusion Stockholders at the Special Meeting. Accordingly, the approval of the Merger Agreement Proposal by Enfusion Stockholders is a condition to the obligations of Clearwater and Enfusion